Why Valeant Pharmaceuticals Intl Inc. Shares Surged as Much as 17% on Monday

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) shares soared after the company announced Michael Pearson will be stepping down.

| More on:
The Motley Fool

On March 21, there were more developments in the Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) saga.

Most notably, the company announced that CEO Michael Pearson will be stepping down as soon as a successor is found. In addition, activist investor Bill Ackman, head of Pershing Square Capital Management, has now joined the board of directors. And to top it all off, Valeant blamed its past financial misstatements on former CFO Howard Schiller and asked him to resign from the board of directors. Yet he has refused to do so.

While these developments may look like signs of chaos, investors reacted warmly to the news, sending Valeant’s shares up by as much as 17%. So why exactly did Valeant’s shares increase, and what does this news mean for the company in the long term?

Michael Pearson’s departure

Michael Pearson has been the face of Valeant’s rise as well as its fall. It was he who moved the company from the United States to Canada primarily for tax reasons. It was he who slashed Valeant’s R&D spending in favour of an acquisition-based model. And as the company finds itself in a downward spiral, he is at the centre of it all.

Up until March he was still held in very high regard. When the Philidor story dominated headlines, Mr. Ackman reiterated his support for Mr. Pearson. Then when Mr. Pearson had to step down at the end of 2015 (for health-related reasons), Valeant’s share price fell. More recently, Nomura Securities analyst Shibani Malhotra said Valeant would lose its competitive advantage if Mr. Pearson stepped down.

But that all changed when Valeant lowered its 2016 guidance on March 14. Now there’s a sense that the company has no idea what it’s doing, which, of course, reflects badly on the CEO. So it’s no surprise that his departure is being received well.

Bill Ackman’s presence

Not unlike Mr. Pearson, Bill Ackman is another public figure whose reputation has taken a dramatic turn for the worse.

Long known as one of Wall Street’s best activist investors, Mr. Ackman has had some remarkable successes; for example, he initiated the turnaround at Canadian Pacific Railway Limited, which has been a tremendous win for shareholders of that company.

But more recently, the story has been very different. When Valeant started running into trouble, he increased his stake, saying his biggest regret was that he wasn’t in a position to buy more shares. He also said that the company’s biggest problem was poor communication. During a conference call, he even predicted that Valeant’s shares would reach US$448 by 2019.

Yet Mr. Ackman still is held in high regard, so his decision to join the board may be viewed as a small positive.

Howard Schiller

It may seem unfair that Mr. Schiller is being made the scapegoat, since he stepped in as interim-CEO during a very difficult time. Then again, he was CFO at a time when the company misstated its financials.

In any case, this controversy is really more of a side story. Mr. Pearson’s departure was certainly the main reason Valeant’s share price increased, and Mr. Ackman’s increased involvement was likely a factor as well. We’ll have to wait and see how this all plays out.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Benjamin Sinclair has no position in any stocks mentioned.  Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

The virtual button with the letters AI in a circle hovering above a keyboard, about to be clicked by a cursor.
Tech Stocks

Emerging Canadian AI Companies With Big Potential

These tech stocks are paving the way to an AI-filled future, but still offer enough growth ahead for a strong…

Read more »

Young Boy with Jet Pack Dreams of Flying
Tech Stocks

Is Constellation Software Stock a Buy, Sell, or Hold for 2025?

CSU stock has long been a strong option for high growth, high value stocks. But are there now too many…

Read more »

rising arrow with flames
Investing

2 Riskier Stocks With High Potential for Canadian Investors in November

Risky stocks such as Well Health Technologies have the potential to provide life-changing long-term returns.

Read more »

hand stacks coins
Dividend Stocks

3 Ultra-High-Yield Dividend Stocks You Can Buy and Hold for a Decade

These three high-yield dividend stocks still have some work to do, but each are in steady areas that are only…

Read more »

senior man and woman stretch their legs on yoga mats outside
Dividend Stocks

TFSA: 2 Canadian Stocks to Buy and Hold Forever

Here are 2 TFSA-worthy Canadian stocks. Which one is a good buy for your TFSA today?

Read more »

Canada day banner background design of flag
Investing

Got $500? 5 Top Canadian Stocks to Buy and Hold

These top Canadian stocks have solid fundamentals with potential to outperform the benchmark index by a wide margin.

Read more »

man touches brain to show a good idea
Energy Stocks

1 No-Brainer Energy Stock to Buy With $500 Right Now

Should you buy a cyclical energy stock at its decade-high? Probably not. But read this before you make a decision.

Read more »

Asset Management
Stocks for Beginners

TFSA: 4 Canadian Stocks to Buy and Hold Forever

Thinking about what to buy with the new TFSA contribution space in 2025? These four Canadian stocks are worth holding…

Read more »